Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 2/20 | 0.62 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.57 |
| ▸ | BRAF | P15056 | 15/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529482 | 0.81 | KDR (0.54) | LCKAURKBCYP3A4KDR | |
| SCHEMBL5109039 | 0.80 | EPHB4 (0.69) | EPHB4BRAFCYP3A4KDR | |
| SCHEMBL3534404 | 0.79 | KDR (0.45) | EPHB4EIF2AK3LCKAURKBCYP3A4 | |
| SCHEMBL3530501 | 0.79 | EPHB4 (0.69) | EPHB4EIF2AK3LCKAURKBEIF2AK1 | |
| SCHEMBL27923236 | 0.79 | EIF2AK3 (0.46) | EPHB4EIF2AK3LCKAURKBEIF2AK1 | |
| SCHEMBL27640679 | 0.77 | KDR (0.42) | EPHB4EIF2AK3LCKAURKBEIF2AK1 | |
| SCHEMBL4474048 | 0.76 | EPHB4 (1.00) | EPHB4BRAFCYP3A4KDR | |
| SCHEMBL868508 | 0.75 | KDR (0.58) | EPHB4EIF2AK3LCKAURKBEIF2AK1 | |
| SCHEMBL3528888 | 0.75 | LCK (0.66) | EIF2AK3LCKAURKBEIF2AK1KDR | |
| SCHEMBL3528886 | 0.75 | LCK (0.66) | EIF2AK3LCKAURKBEIF2AK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255184-A1 | Thienopyridine B-Raf Kinase Inhibitors | BRAF, RAF1, ARAF | EPHB4 651/4885EIF2AK3 1844/4885LCK 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.